AR047890A1 - Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3 - Google Patents

Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3

Info

Publication number
AR047890A1
AR047890A1 ARP050100632A ARP050100632A AR047890A1 AR 047890 A1 AR047890 A1 AR 047890A1 AR P050100632 A ARP050100632 A AR P050100632A AR P050100632 A ARP050100632 A AR P050100632A AR 047890 A1 AR047890 A1 AR 047890A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
alkanoyl
haloalkyl
cyano
Prior art date
Application number
ARP050100632A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403990A external-priority patent/GB0403990D0/en
Priority claimed from GB0404083A external-priority patent/GB0404083D0/en
Priority claimed from GB0417120A external-priority patent/GB0417120D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR047890A1 publication Critical patent/AR047890A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Abstract

Compuestos novedosos de la formula (1) o una sal farmacéuticamente aceptable de los mismos, en los que: G se selecciona de un grupo que consiste en: fenilo, piridilo, benzotiazolilo, indazolilo; p es un numero entero que varía desde 0 a 5; R1 se selecciona independiente de un grupo que consiste en: halogeno, hidroxi, ciano, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, alcanoilo 1-4; o corresponde a un grupo R5; R2 es hidrogeno o alquilo C1-4; R3 es alquilo C1-4; R4 es hidrogeno, o un grupo fenilo, un grupo heterociclilo, un grupo heteroaromático de 5 o 6 miembros, o un grupo bicíclico de 8 a 11 miembros, estando cualquiera de tales grupos opcionalmente sustituido por 1, 2, 3 o 4 sustituyentes que se seleccionan del grupo que consiste en: halogeno, ciano, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, alcanoilo C1-4; R5 es un resto que se selecciona del grupo que consiste en: isoxazolilo, CH2-N-pirrolilo, 1,1-dioxido-2-isotiazolidinilo, tienilo, tiazolilo, piridilo, 2-pirrolidinilo, y un grupo así está opcionalmente sustituido por uno o dos sustituyentes que se seleccionan de: halogeno, ciano, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, alcanoilo C1-4; y cuando R1 es cloro y p es 1, tal R1 no está presente en posicion orto con respecto al enlace de union con el resto de la molécula; y cuando R1 corresponde a R5, p es 1; procedimientos para su preparacion, intermedios que se usan en estos procedimientos, composiciones farmacéuticas que los contienen y su uso en terapia, como moduladora de los receptores de dopamina D3, por ejemplo para tratar drogodependencias o como agentes antipsicoticos.
ARP050100632A 2004-02-23 2005-02-21 Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3 AR047890A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0403990A GB0403990D0 (en) 2004-02-23 2004-02-23 Compounds
GB0404083A GB0404083D0 (en) 2004-02-24 2004-02-24 Compounds
GB0417120A GB0417120D0 (en) 2004-07-30 2004-07-30 Compounds

Publications (1)

Publication Number Publication Date
AR047890A1 true AR047890A1 (es) 2006-03-01

Family

ID=34890800

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100632A AR047890A1 (es) 2004-02-23 2005-02-21 Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3

Country Status (26)

Country Link
US (3) US7855298B2 (es)
EP (3) EP2060570B1 (es)
JP (1) JP4960217B2 (es)
KR (1) KR101143718B1 (es)
CN (1) CN1946714B (es)
AR (1) AR047890A1 (es)
AT (3) ATE451364T1 (es)
AU (2) AU2005215918C1 (es)
BR (1) BRPI0507945A (es)
CA (1) CA2557115C (es)
CY (3) CY1109854T1 (es)
DE (1) DE602005018190D1 (es)
DK (3) DK1745040T3 (es)
ES (2) ES2337590T3 (es)
HK (1) HK1103016A1 (es)
HR (3) HRP20100114T1 (es)
IL (1) IL177184A0 (es)
MA (1) MA28438B1 (es)
NO (1) NO20064309L (es)
PE (1) PE20051173A1 (es)
PL (3) PL1745040T3 (es)
PT (3) PT2060570E (es)
RU (1) RU2434011C2 (es)
SI (3) SI1745040T1 (es)
TW (1) TW200538113A (es)
WO (1) WO2005080382A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1745040T3 (pl) * 2004-02-23 2010-05-31 Glaxo Group Ltd Pochodne azabicyklo(3.1.0)heksanu użyteczne jako modulatory receptorów dopaminowych D3
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
US7807698B2 (en) 2005-06-14 2010-10-05 Glaxo Group Limited Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
WO2007006117A1 (en) * 2005-07-13 2007-01-18 Nicogen Inc. Novel cyp2a6 inhibitors
BRPI0613943B1 (pt) 2005-07-27 2021-06-22 Otsuka America Pharmaceutical, Inc Composto, composição farmacêutica o compreendendo, usos de um composto e de uma composição farmacêutica, bem como composição neurobiologicamente ativa
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
WO2007022933A1 (en) * 2005-08-22 2007-03-01 Glaxo Group Limited Triazole derivatives as modulators of dopamine d3 receptors
DE602007012531D1 (de) * 2006-04-03 2011-03-31 Glaxo Group Ltd Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
MX2008012875A (es) * 2006-04-03 2008-10-13 Glaxo Group Ltd Derivados de azabiciclo [3.1.0] hexilo como moduladores de los receptores d3 de la dopamina.
GB0703387D0 (en) * 2007-02-21 2007-03-28 Glaxo Group Ltd Novel compounds
GB0607899D0 (en) 2006-04-03 2006-05-31 Glaxo Group Ltd Process for preparing heterocyclic derivatives
JP5189076B2 (ja) * 2006-04-03 2013-04-24 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキシル誘導体
GB0608452D0 (en) * 2006-04-27 2006-06-07 Glaxo Group Ltd Novel compounds
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
EP2167083B1 (en) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0719234D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
GB0719235D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
AU2009271325A1 (en) 2008-06-24 2010-01-21 Merck Sharp & Dohme Corp. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
MX2011003011A (es) 2008-09-22 2011-09-01 Cayman Chem Co Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyetica y su uso para tratar enfermedades mediadas por prostaglandina d2.
WO2010150281A2 (en) * 2009-06-26 2010-12-29 Panacea Biotec Ltd. Novel azabicyclohexanes
US20160279098A1 (en) * 2013-11-11 2016-09-29 Euthymics Bioscience, Inc. Novel methods
US10273244B2 (en) * 2015-08-05 2019-04-30 Indivior Uk Limited Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators
WO2019146740A1 (ja) 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
KR20230027245A (ko) 2020-06-22 2023-02-27 코어셉트 쎄라퓨틱스 인코포레이티드 4차 인다졸 글루코코르티코이드 수용체 길항제
US20230242514A1 (en) * 2021-12-21 2023-08-03 Corcept Therapeutics Incorporated Bicyclic indazole glucocorticoid receptor antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022230A1 (es) * 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
KR20030045187A (ko) 2000-11-14 2003-06-09 스미스클라인비이참피이엘시이 도파민 ｄ₃수용체 조절제 (정신병 치료제)로서 유용한테트라히드로벤즈아제핀 유도체
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
DE60226161T2 (de) 2001-10-22 2009-07-02 Pfizer Products Inc., Groton 3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
IL166510A0 (en) * 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
PL1745040T3 (pl) * 2004-02-23 2010-05-31 Glaxo Group Ltd Pochodne azabicyklo(3.1.0)heksanu użyteczne jako modulatory receptorów dopaminowych D3
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
US7807698B2 (en) * 2005-06-14 2010-10-05 Glaxo Group Limited Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
WO2007022933A1 (en) * 2005-08-22 2007-03-01 Glaxo Group Limited Triazole derivatives as modulators of dopamine d3 receptors
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
MX2008012875A (es) * 2006-04-03 2008-10-13 Glaxo Group Ltd Derivados de azabiciclo [3.1.0] hexilo como moduladores de los receptores d3 de la dopamina.
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
DK2070922T3 (da) 2011-11-28
HK1103016A1 (en) 2007-12-14
AU2005215918C1 (en) 2010-01-21
CA2557115C (en) 2012-10-02
EP2070922B1 (en) 2011-08-17
DK1745040T3 (da) 2010-04-12
US20100152195A1 (en) 2010-06-17
PL2060570T3 (pl) 2012-06-29
US8283474B2 (en) 2012-10-09
IL177184A0 (en) 2006-12-10
HRP20100114T1 (hr) 2010-04-30
PL2070922T3 (pl) 2012-01-31
JP4960217B2 (ja) 2012-06-27
CN1946714A (zh) 2007-04-11
EP2060570B1 (en) 2012-01-25
HRP20110781T1 (hr) 2011-11-30
RU2434011C2 (ru) 2011-11-20
ATE542816T1 (de) 2012-02-15
AU2005215918A1 (en) 2005-09-01
KR20060127991A (ko) 2006-12-13
US20100160336A1 (en) 2010-06-24
NO20064309L (no) 2006-11-23
BRPI0507945A (pt) 2007-07-24
EP2060570A3 (en) 2009-06-03
KR101143718B1 (ko) 2012-07-05
ATE451364T1 (de) 2009-12-15
EP2060570A2 (en) 2009-05-20
DK2060570T3 (da) 2012-04-30
CN1946714B (zh) 2011-06-15
US20070142438A1 (en) 2007-06-21
JP2007523208A (ja) 2007-08-16
PL1745040T3 (pl) 2010-05-31
PE20051173A1 (es) 2006-02-14
CY1113029T1 (el) 2016-04-13
TW200538113A (en) 2005-12-01
ES2337590T3 (es) 2010-04-27
SI2070922T1 (sl) 2011-12-30
AU2005215918B2 (en) 2009-06-11
WO2005080382A1 (en) 2005-09-01
SI2060570T1 (sl) 2012-05-31
AU2009212887A1 (en) 2009-09-24
EP1745040A1 (en) 2007-01-24
EP1745040B9 (en) 2010-06-02
RU2006133909A (ru) 2008-03-27
PT1745040E (pt) 2010-03-08
HRP20120281T1 (hr) 2012-04-30
US7855298B2 (en) 2010-12-21
PT2060570E (pt) 2012-05-07
SI1745040T1 (sl) 2010-04-30
CY1109854T1 (el) 2014-09-10
EP1745040B1 (en) 2009-12-09
PT2070922E (pt) 2011-11-24
CY1112011T1 (el) 2015-11-04
US8263782B2 (en) 2012-09-11
EP2070922A1 (en) 2009-06-17
CA2557115A1 (en) 2005-09-01
ES2380990T3 (es) 2012-05-22
ATE520686T1 (de) 2011-09-15
DE602005018190D1 (de) 2010-01-21
MA28438B1 (fr) 2007-02-01

Similar Documents

Publication Publication Date Title
AR047890A1 (es) Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3
AR060237A1 (es) Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende.
ATE487715T1 (de) Triazolderivate als modulatoren von dopamin-d3- rezeptoren
AR062360A1 (es) Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa
MY144048A (en) Chemical compound
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
AR070636A1 (es) Derivados de piridina, composicion farmaceutica y uso terapeutico
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR074238A1 (es) Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
AR057855A1 (es) Derivados de pirazina y composicion farmaceutica
GB0507680D0 (en) Compounds
AR061134A1 (es) Derivados de tioxantina
AR062737A1 (es) Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento
AR064831A1 (es) Derivados de espiropiperidina-glicinamida
AR075367A1 (es) Inhibidores de glucosilceramida sintasa
PE20190980A1 (es) Compuestos terapeuticos y metodos para utilizarlos
AR116022A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
PE20201068A1 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones

Legal Events

Date Code Title Description
FA Abandonment or withdrawal